TransCure bioServices strengthens team with C-suite hire and boosts North American preclinical opportunitiesDecember 13, 2023
A full-time CFO supports growth, while the new US-registered company grants locals end-to-end preclinical services access
TransCure bioServices, an AAALAC-accredited supplier of advanced humanized preclinical mouse models, is thrilled to announce the appointment of Céline Pinault as its new Chief Financial Officer. Pinault brings extensive experience in finance and business strategy, and her arrival marks a significant step in the company’s expansion. As part of this growth, TransCure bioServices has also registered a US company, increasing its reach in North America.
Céline Pinault joins TransCure bioServices with a robust background in financial management and strategic planning. Drawing on over 15 years of experience in finance leadership positions at well-established companies including AplusA, 5àsec and IPSOS, Pinault’s focus will be on driving the company’s global growth by acting as a specialist strategic finance officer.
“It’s an exciting time to join TransCure bioServices, as it continues to go from strength to strength,” says Pinault. “I look forward to helping the company deliver its ambitious global growth plans in a viable and sustainable manner. This will enable TransCure to help more customers bring novel therapeutics to market to overcome global healthcare challenges.”
As part of its growth plans, TransCure bioServices aims to provide all biotechnology and pharmaceutical companies the same wide range of technical services globally. While the CRO has been able to cater for North American customers from abroad, shipping and complex import regulations have caused challenges for both TransCure bioServices and its customers.
Now, the CRO has registered TransCure bioServices Inc. in the US to provide its North American customers with all the preclinical services offered in Europe. As a result, drug developers in the region get the same range of benefits in working with an end-to-end partner as their European counterparts, including the rapid delivery times they need to keep their studies on track.
“For safe and efficacious treatments to be brought to market quickly, it’s essential that researchers have access to high-quality preclinical services to support drug development,” says Kiave Ho Wang Yin, PhD, Chief Business and Innovation Officer at TransCure bioServices. “Between our existing sites, our new North American registration, and our recent Preclina partnership in the APAC region, we’re able to provide near-global support for organizations striving to advance healthcare.”
To learn more about TransCure bioServices’ offerings and leadership team, please click here: https://transcurebioservices.com/about-us/
About TransCure bioServices:
TransCure bioServices is a unique fee-for-service Contract Research Organization (CRO) with expertise in conducting research using humanized mouse models, supported by cutting edge technologies. The company offers qualified services across a range of disease models, from preliminary discussion through tailor-made protocols, experiments, and reporting. TransCure bioServices adheres to rigorous standards including AALAC accreditation and the three R’s: Replacement, Reduction, and Refinement of responsible animal use.
Clinical Research & Trials,
Corporate, Finance & Investor